Bifidobacterium animalis DN-173010

Bifidobacterium animalis DN-173010 is a proprietary probiotic strain commercialized as Bifidus Digestivum (Activia) that accelerates gastrointestinal transit by modulating gut motility signaling and altering colonic microbiota composition. Its primary mechanism involves increasing intestinal peristalsis and reducing colonic transit time, with documented efficacy in constipation and IBS-C.

Origin & History

Bifidobacterium animalis DN-173010 is a specific probiotic bacterium strain originally isolated from fermented dairy products like yogurt. It is produced industrially through fermentation processes with dairy substrates and starter cultures including Streptococcus thermophilus and Lactobacillus bulgaricus, or manufactured in lyophilized (freeze-dried) powder form for enhanced stability.

Historical & Cultural Context

No historical or traditional medicine use is documented for this specific strain. DN-173010 is a modern, industrially-selected probiotic developed for commercial fermented dairy products, with clinical evidence beginning only from 2002 onward.

Health Benefits

• Reduces colonic transit time in healthy women by ~20% (RCT, n=36, PMID: 11876714)
• Increases stool frequency and improves defecation conditions in constipated women (RCT, n=135)
• Improves quality of life, bloating, and stool frequency in IBS patients with constipation (RCT, PMID: 17635382)
• Reduces total microbial counts in saliva, supporting oral health (clinical study, PMID: 24217196)
• Demonstrates 20-22% survival through GI transit with viable colonization at ≥10^8 CFU/g in feces (RCT, n=12, PMID: 17957120)

How It Works

B. animalis DN-173010 colonizes the colon transiently and produces short-chain fatty acids (SCFAs), including acetate and lactate, which stimulate colonic smooth muscle contractions via free fatty acid receptors (FFAR2/GPR43), accelerating peristalsis. The strain also modulates the gut-brain axis by influencing serotonin (5-HT) availability in enteroendocrine cells, which regulates intestinal motility through 5-HT4 receptor activation. Additionally, it competitively excludes pathogenic bacteria and reduces intestinal permeability by upregulating tight junction proteins such as occludin and claudin-1, contributing to reduced bloating and improved stool consistency.

Scientific Research

Multiple randomized controlled trials demonstrate efficacy, including a crossover RCT (n=36, PMID: 11876714) showing shortened colonic transit times, and a larger trial (n=135) confirming improved stool frequency in constipated women. An IBS-focused RCT (PMID: 17635382) showed improvements in quality of life and bloating, while meta-analyses confirm GI benefits for related B. lactis strains.

Clinical Summary

A double-blind RCT (n=36 healthy women, PMID: 11876714) demonstrated that daily consumption of yogurt containing DN-173010 reduced oro-anal transit time by approximately 20% compared to placebo. A larger RCT (n=135 constipated women) confirmed increased stool frequency and improved defecation conditions, including reduced straining and harder stool normalization. In IBS patients with constipation, a randomized controlled trial (PMID: 17635382) reported significant improvements in quality of life scores, bloating severity, and stool frequency versus control. Evidence is strongest for constipation in women, with most trials industry-sponsored and limited in duration (typically 2–4 weeks), warranting cautious generalization.

Nutritional Profile

Bifidobacterium animalis subsp. lactis DN-173 010 is a proprietary probiotic strain (commercialized as 'Bifidus regularis'/'Bifidus ActiRegularis' by Danone, primarily delivered via Activia® fermented milk products). As a living microorganism, the strain itself does not contribute significant macronutrients; its value is in its bioactive and functional properties. **Typical delivery vehicle (per ~125 g serving of Activia fermented milk):** Calories: ~80–100 kcal; Protein: ~5–6 g (primarily caseins and whey proteins, with enhanced bioavailability due to partial proteolysis during fermentation); Fat: ~1.5–3 g (depending on skim/low-fat formulation); Carbohydrates: ~12–15 g (lactose partially hydrolyzed during fermentation, reducing it by ~20–30%; residual sugars and sometimes added sugars); Calcium: ~150–180 mg (~15–18% RDI, with improved bioavailability due to lactic acid-mediated solubilization and lower pH); Phosphorus: ~100–120 mg; Potassium: ~200 mg; Vitamin B12: ~0.3–0.5 µg (produced in part by bacterial metabolism); Riboflavin (B2): ~0.2–0.3 mg; Folate (B9): trace amounts synthesized by bifidobacteria (~5–15 µg). **Bioactive compounds from the strain and fermentation process:** Viable probiotic cell count: ≥10^8–10^9 CFU per serving (typically guaranteed ≥10^7 CFU/g at end of shelf life, with Danone historically guaranteeing ~10^10 CFU per pot); Exopolysaccharides (EPS): produced during fermentation, contribute to viscosity and may have immunomodulatory and prebiotic-like properties (concentration variable, estimated µg–low mg range per serving); Short-chain fatty acids (SCFAs): acetate and lactate are primary fermentation end-products of B. animalis (acetate: ~5–15 mM in the fermented product; L-lactic acid: ~8–12 g/L); Conjugated linoleic acid (CLA): trace amounts potentially generated during milk fat bioconversion; Bioactive peptides: generated from casein hydrolysis during fermentation, including ACE-inhibitory peptides (VPP, IPP at µg/mL levels) with potential antihypertensive activity; Bacteriocin-like inhibitory substances (BLIS): produced by the strain, contributing to competitive exclusion of pathogens in the gut; β-galactosidase: enzyme produced by the strain that persists in the gut and aids lactose digestion in vivo (relevant for lactose-intolerant individuals). **Bioavailability notes:** The fermented milk matrix significantly enhances probiotic survival through gastric transit (buffering capacity of milk proteins maintains pH >4 in stomach, improving strain viability by 10–100× compared to non-dairy delivery); bile salt hydrolase (BSH) activity intrinsic to DN-173 010 further supports survival in the upper GI tract; the strain has demonstrated the ability to survive and remain metabolically active through the entire GI tract, with recovery in feces at ~10^6–10^8 CFU/g after regular consumption; calcium bioavailability is enhanced ~10–15% compared to unfermented milk due to acidic pH and caseinophosphopeptide release; B-vitamin bioavailability from bacterial synthesis is moderate but contributes meaningfully to daily intake when consumed regularly.

Preparation & Dosage

Clinically studied dosage: 1.25×10^10 CFU per 125g serving of fermented milk, consumed 1-3 times daily for 1-2 weeks. Lyophilized powder forms achieve equivalent doses with ≥10^8 CFU/g fecal survival. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Streptococcus thermophilus, Lactobacillus bulgaricus, Lactobacillus acidophilus, Inulin, Psyllium husk

Safety & Interactions

B. animalis DN-173010 is generally recognized as safe (GRAS) for healthy adults and has shown no serious adverse events across published clinical trials. Mild gastrointestinal side effects such as transient bloating or increased flatulence may occur during the first few days of use as the microbiome adjusts. Immunocompromised individuals, those with central venous catheters, or patients recovering from intestinal surgery should consult a physician before use, as rare cases of probiotic-associated bacteremia have been reported with Bifidobacterium species in vulnerable populations. No significant drug interactions have been formally documented, though concurrent antibiotic use will reduce strain viability and efficacy; spacing intake at least 2 hours from antibiotics is commonly advised.